Sanofi Pasteur and Merck plan to end their joint vaccines operations in Europe. After concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue separate growth strategies in Europe.
 
The joint venture Sanofi Pasteur MSD, owned on a 50/50 basis, was created in 1994 to develop and commercialize vaccines from both companies’ pipelines in 19 European countries. Numerous vaccines from Sanofi and MSD’s development pipelines were launched, addressing key unmet medical needs.
 
Sanofi Pasteur and MSD jointly issued the following statement, “We are proud of Sanofi Pasteur MSD’s successful 20-year history. Our joint venture has achieved considerable success over the past two decades from a public health and commercial perspective. After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently. We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimize vaccine coverage. By bringing vaccines more rapidly to market, both companies would deliver greater value to all stakeholders.”
 
The companies expect the project to be completed by the end of 2016, subject to local labor laws and regulations and regulatory approvals.